These findings define LSD1 as a master repressor of epithelial immune competence and nominate LSD1 inhibition as a therapeutic strategy to activate retinoid-AP-1 enhancer circuits and drive CD4-dependent tumor immunity in skin cancer. Here, CD4 is linked to skin cancer.